There are 2789 resources available
1006P - ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 3+ tumors
Presenter: Sarina Piha-Paul
Session: ePoster Display
1007P - T-cells transgenic for a highly potent PRAME-specific TCR and a chimeric PD1-41BB co-stimulatory receptor represent a promising approach for the treatment of solid tumors
Presenter: Maja Bürdek
Session: ePoster Display
951P - Application of deep learning on whole-slide images to predict relapse-free survival of hepatocellular carcinoma patients following liver transplant
Presenter: Daniel Roberts
Session: ePoster Display
952P - Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib
Presenter: Dong-Hoon Lim
Session: ePoster Display
953P - Trends in disease burden from hepatocellular carcinoma: An observational study of European union 15+ countries
Presenter: Georgina Hanbury
Session: ePoster Display
954P - Comparison of medical costs and outcome between hepatectomy and radiofrequency ablation for hepatocellular carcinoma
Presenter: Takeshi Terashima
Session: ePoster Display
955P - Prognostic factor analysis of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: Korean cancer study group (KCSG) study
Presenter: Jaekyung Cheon
Session: ePoster Display
956P - A multi-analyte liquid biopsy assay integrating cfDNA methylation and protein biomarkers for liver cancer diagnosis
Presenter: Dezhen Guo
Session: ePoster Display
966P - Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy
Presenter: Alessio Cortellini
Session: ePoster Display
967P - The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer
Presenter: Anna Vilalta
Session: ePoster Display